Jump to content

József Knoll

From Wikipedia, the free encyclopedia
József Knoll
MD, PhD, DSc
Born(1925-05-30)May 30, 1925[1]
DiedApril 17, 2018(2018-04-17) (aged 92)[1]
Other namesJoseph Knoll; Jozsef Knoll
OccupationPsychopharmacologist

József Knoll (May 30, 1925 – April 17, 2018), or Joseph Knoll, was a Hungarian psychopharmacologist known for developing the antiparkinsonian and antidepressant drug selegiline (L-deprenyl).[2][3][4][1][5]

He developed selegiline in the 1960s and subsequently studied the drug and related agents for many decades.[2][1][4] Knoll also developed the concepts of monoaminergic activity enhancers (MAEs) and the mesencephalic enhancer regulation system, among other contributions.[2][1] MAEs developed by Knoll and colleagues include selegiline, benzofuranylpropylaminopentane (BPAP), and phenylpropylaminopentane (PPAP), among others.[2]

During his scientific career, Knoll published 894 papers and was the originator of 55 patents.[1] As of 2018, his papers had been cited more than 10,000 times.[1] He is described as one of the best-known Hungarian pharmacologists.[1]

Knoll is known for having extensively researched and promoted selegiline for claimed drive- and longevity-enhancing effects related to its MAE activity.[2][4][1][5] Knoll himself began taking a low 1 mg daily dose of selegiline on January 1, 1989 at the age of 64.[6]: 92 [3] He reported in 2012 that this had continued for 22 years uninterrupted.[6]: 92  Knoll stated that he had become so fascinated with the possible longevity-promoting effects of selegiline he was studying that he had decided to start taking it as a self-experiment.[6]: 92 [3] Knoll later died in 2018 at the age of 93.[4]

Selected publications

[edit]

Books

[edit]
  • Knoll J (2005). The Brain and Its Self: A Neurochemical Concept of the Innate and Acquired Drives. Berlin/Heidelberg: Springer-Verlag. ISBN 978-3-540-23969-7.
  • Knoll J (2012). How Selegiline ((-)-Deprenyl) Slows Brain Aging. Bentham Science Publishers. ISBN 978-1-60805-470-1. Retrieved 4 July 2024.

Reviews

[edit]

References

[edit]
  1. ^ a b c d e f g h i Ildiko Miklya (September 20, 2018). "In Memoriam: Joseph Knoll (1925 – 2018)" (PDF). International Network for the History of Neuropsychopharmacology (INHN). Retrieved 15 August 2024. He was one of the internationally best known Hungarian pharmacologists [...] He described the details of his work published with his pupils in 894 papers (citations: 10,055) and was the originator of 55 patents.
  2. ^ a b c d e Miklya I (November 2016). "The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015)". Mol Psychiatry. 21 (11): 1499–1503. doi:10.1038/mp.2016.127. PMID 27480491.
  3. ^ a b c Healy D (2000). "The Psychopharmacology of Life and Death. Interview with Joseph Knoll.". The Psychopharmacologists, Vol. III: Interviews. London: Arnold. pp. 81–110. doi:10.4324/9781003058892-3. ISBN 978-0-340-76110-6.
  4. ^ a b c d Ferdinandy P, Yoneda F, Muraoka S, Fürst S, Gyires K, Miklya I (February 2020). "Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues". European Journal of Pharmacology. 868: 172793. doi:10.1016/j.ejphar.2019.172793. PMID 31743738. S2CID 208185366.
  5. ^ a b Thomas A. Ban (November 8, 2018). "In Memory of Joseph Knoll (1925 – 2018)" (PDF). International Network for the History of Neuropsychopharmacology (INHN). Retrieved 15 August 2024.
  6. ^ a b c Knoll J (2012). How Selegiline ((-)-Deprenyl) Slows Brain Aging. Bentham Science Publishers. ISBN 978-1-60805-470-1. Retrieved 4 July 2024.
[edit]